在美国全国性肝硬化队列中验证新型脂肪性肝病命名并对其进行流行病学定义
研究在美国全国性肝硬化退伍军人队列中开发7种算法定义酒精相关性肝病、代谢功能障碍相关脂肪性肝病及代谢功能障碍相关脂肪性肝病伴酒精摄入增加,主要结局为脂肪性肝病分类,并用主要急性心脏事件住院和酒精使用障碍住院验证。31,514例患者中,不同算法下代谢功能障碍相关脂肪性肝病伴酒精摄入增加占比4.7%至47.2%不等,酒精相关性肝病较代谢功能障碍相关脂肪性肝病死亡风险更高(HR 1.41,95%CI 1.34-1.48)。结论认为脂肪性肝病分类对心血管代谢危险因素与酒精使用的相对权重高度敏感。
要点
- 不同算法下代谢功能障碍相关脂肪性肝病伴酒精摄入增加占比从4.7%到47.2%不等。
- 方法4下主要急性心脏事件住院率:代谢功能障碍相关脂肪性肝病16.7、代谢功能障碍相关脂肪性肝病伴酒精摄入增加14.5、酒精相关性肝病8.4每100人年。
- 酒精相关性肝病较代谢功能障碍相关脂肪性肝病死亡风险更高(HR 1.41,95%CI 1.34-1.48)。
核心结论
- 脂肪性肝病分类对心血管代谢危险因素与酒精使用的相对权重高度敏感。
- 临床相关定义应考虑酒精数据的可获得性以及血脂测量在区分脂肪性肝病亚型中的局限性。
研究设计与样本
- 在美国全国性肝硬化退伍军人队列中,纳入影像学证实脂肪变的肝硬化患者31,514例(中位年龄64岁)。
- 开发7种算法,对心血管代谢危险因素和酒精暴露给予不同权重,以定义酒精相关性肝病、代谢功能障碍相关脂肪性肝病及代谢功能障碍相关脂肪性肝病伴酒精摄入增加。
主要发现
- 心血管代谢危险因素(≥1个者占98.8%)和有害酒精使用(65.3%)高度流行。
- 不同分类方法下代谢功能障碍相关脂肪性肝病、代谢功能障碍相关脂肪性肝病伴酒精摄入增加和酒精相关性肝病的分布差异很大,例如代谢功能障碍相关脂肪性肝病伴酒精摄入增加占比从4.7%到47.2%不等。
- 方法4下主要急性心脏事件住院发生率在代谢功能障碍相关脂肪性肝病、代谢功能障碍相关脂肪性肝病伴酒精摄入增加和酒精相关性肝病中分别为16.7、14.5和8.4每100人年。
- 方法4下酒精使用障碍住院发生率在代谢功能障碍相关脂肪性肝病、代谢功能障碍相关脂肪性肝病伴酒精摄入增加和酒精相关性肝病中分别为2.0、26.1和47.6每100人年。
- 高甘油三酯血症和低高密度脂蛋白在各脂肪性肝病亚型中均常见,包括酒精相关性肝病(高甘油三酯血症67.3%;低高密度脂蛋白48.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Novel steatotic liver disease (SLD) definitions were introduced in 2023. Accurate and meaningful classifications using clinical data are needed to study interventions and outcomes. METHODS: In a national cohort of Veterans with cirrhosis and imaging-confirmed steatosis, 7 algorithms differentially emphasizing cardiometabolic risk factors (CMRFs) and alcohol exposure were developed to define alcohol-associated liver disease (ALD), metabolic dysfunction associated SLD (MASLD), and MASLD with increased alcohol intake (MetALD). The primary outcome was classification of SLD, which was validated using hospitalizations for major acute cardiac events (MACE) and alcohol use disorder (AUD). Secondary outcomes included longitudinal Child-Turcotte-Pugh class, incident hepatocellular carcinoma, and all-cause mortality. RESULTS: In all, 31,514 patients with cirrhosis (median age 64 years) were included. CMRFs (98.8% ≥ 1) and hazardous alcohol use (65.3%) were highly prevalent. The distributions of MASLD, MetALD, and ALD varied substantially across classification methods with varying CMRF and alcohol criteria. For example, MetALD ranged from 4.7% to 47.2%. Using method 4, incidence rates of MACE hospitalizations in MASLD, MetALD, and ALD were 16.7, 14.5, and 8.4 per 100 person-years, respectively, and incidence rates of AUD hospitalizations were 2.0, 26.1, and 47.6 per 100 person-years, respectively. Hypertriglyceridemia and low high-density lipoprotein were common across SLD subtypes, including ALD (67.3% hypertriglyceridemia; 48.2% low high-density lipoprotein). Patients with ALD (hazard ratio, 1.41; 95% confidence interval, 1.34-1.48) had significantly higher hazards of mortality relative to MASLD. CONCLUSION: Classification of SLD is highly sensitive to relative weighting of CMRFs and alcohol use. Clinically relevant definitions should consider data availability on alcohol and the limitations of lipid measurements in distinguishing SLD subtypes.
引用
- Mezzacappa C, Ochoa-Allemant P, Serper M, et al. Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis. Clin Gastroenterol Hepatol. 2024. PMID: 39689774. doi:10.1016/j.cgh.2024.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。